相似文献
1
Malignant pleural mesothelioma: current and future perspectives.
J Thorac Dis. 2013 Sep;5 Suppl 4(Suppl 4):S397-406. doi: 10.3978/j.issn.2072-1439.2013.08.08.
2
Surgery for malignant pleural mesothelioma: why, when and what?
Lung Cancer. 2014 May;84(2):103-9. doi: 10.1016/j.lungcan.2014.01.021. Epub 2014 Feb 3.
3
[Pleural effusion cytology of asbestos-associated malignant mesothelioma and lung carcinoma in the diagnosis of occupational diseases by the statutory accident insurance funds].
Pneumologie. 2014 Apr;68(4):270-6. doi: 10.1055/s-0034-1365157. Epub 2014 Mar 10.
4
The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma.
Semin Thorac Cardiovasc Surg. 2013 Summer;25(2):125-43. doi: 10.1053/j.semtcvs.2013.07.002.
5
[Malignant pleural mesothelioma].
Ther Umsch. 2012 Jul;69(7):401-5. doi: 10.1024/0040-5930/a000306.
6
Malignant mesothelioma: options for management.
Surg Clin North Am. 2002 Aug;82(4):797-831. doi: 10.1016/s0039-6109(02)00033-6.
7
[Malignant pleural mesothelioma: early diagnosis and multimodality management].
G Chir. 2005 Jun-Jul;26(6-7):257-60.
8
[Video-assisted thoracoscopic surgery in diagnostic and treatment of non-operable malignant pleural mesothelioma].
Khirurgiia (Sofiia). 2007(4):23-6.
9
[Malignant pleural mesothelioma: 2013 state of the art].
Bull Cancer. 2013 Dec;100(12):1283-93. doi: 10.1684/bdc.2013.1857.
10
A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.
J Thorac Oncol. 2019 Aug;14(8):1343-1353. doi: 10.1016/j.jtho.2019.04.029. Epub 2019 May 25.
引用本文的文献
1
Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer.
Mol Oncol. 2024 Apr;18(4):797-814. doi: 10.1002/1878-0261.13591. Epub 2024 Mar 8.
2
Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients.
World J Surg Oncol. 2022 Jun 29;20(1):219. doi: 10.1186/s12957-022-02688-x.
3
Mesothelioma: A Case in a Diagnostic Timeline and the Efficiency of Robot-Assisted Surgery.
Case Rep Oncol. 2022 Mar 3;15(1):149-155. doi: 10.1159/000522114. eCollection 2022 Jan-Apr.
4
Cerebral metastases of malignant mesothelioma.
J Surg Case Rep. 2022 Feb 6;2022(2):rjac002. doi: 10.1093/jscr/rjac002. eCollection 2022 Feb.
5
Lung cancer biopsies: Comparison between simple 22G, 22G upgraded and 21G needle for EBUS-TBNA.
J Cancer. 2020 Sep 14;11(21):6454-6459. doi: 10.7150/jca.48691. eCollection 2020.
6
Diagnostic Utility of N-terminal pro-Brain Natriuretic Peptide and C-reactive Protein in Diagnosing Heart Failure in Patients with Acute Hypoxemic Respiratory Failure.
Cureus. 2020 Jan 31;12(1):e6835. doi: 10.7759/cureus.6835.
7
Relations between approved platinum drugs and non-coding RNAs in mesothelioma.
Noncoding RNA Res. 2018 Aug 30;3(4):161-173. doi: 10.1016/j.ncrna.2018.08.001. eCollection 2018 Dec.
8
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.
J Thorac Dis. 2018 Jan;10(Suppl 2):S207-S220. doi: 10.21037/jtd.2017.10.74.
9
Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.
Front Genet. 2017 May 29;8:70. doi: 10.3389/fgene.2017.00070. eCollection 2017.
10
CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
Respir Res. 2017 Apr 12;18(1):58. doi: 10.1186/s12931-017-0546-5.
本文引用的文献
1
Clinical advances in molecular biomarkers for cancer diagnosis and therapy.
Int J Mol Sci. 2013 Jul 16;14(7):14771-84. doi: 10.3390/ijms140714771.
2
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
Br J Cancer. 2013 Aug 6;109(3):552-8. doi: 10.1038/bjc.2013.368. Epub 2013 Jul 16.
3
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
J Clin Pathol. 2013 Oct;66(10):847-53. doi: 10.1136/jclinpath-2012-201303. Epub 2013 Jun 27.
4
ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
Clin Lung Cancer. 2013 Sep;14(5):558-567.e3. doi: 10.1016/j.cllc.2013.04.013. Epub 2013 Jun 27.
5
Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.
Cancer Chemother Pharmacol. 2013 Aug;72(2):429-35. doi: 10.1007/s00280-013-2216-8. Epub 2013 Jun 26.
6
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
Eur J Cancer. 2013 Sep;49(13):2815-22. doi: 10.1016/j.ejca.2013.05.008. Epub 2013 Jun 20.
7
The role of epigenetics in malignant pleural mesothelioma.
Lung Cancer. 2013 Sep;81(3):311-318. doi: 10.1016/j.lungcan.2013.05.014. Epub 2013 Jun 18.
8
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
Lung Cancer. 2013 Sep;81(3):422-427. doi: 10.1016/j.lungcan.2013.05.006. Epub 2013 Jun 17.
9
Personalized medicine in oncology: where have we come from and where are we going?
Pharmacogenomics. 2013 Jun;14(8):931-9. doi: 10.2217/pgs.13.79.
10
An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment.
Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):1037-51. doi: 10.1517/17425255.2013.804065. Epub 2013 May 27.
Zotero 插件